Evidence map›Paper›PMID 41683948›Full record

ArticleInternational journal of molecular sciences2026

Seco-Duocarmycin SA Augments the Impact of Proton Radiation on Human Glioblastoma Cells.

Ann Morcos, Joab Galvan Bustillos, Yeonkyu Jung, Ryan N Fuller, Antonella Bertucci, David Caba Molina, Amy Nguyen, Quanqing Zhang, Kristopher E Boyle, William H R Langridge and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ann MorcosDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Joab Galvan BustillosDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Yeonkyu JungDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.ORCID 0009-0003-2060-1858
Ryan N FullerDepartment of Biological Sciences, California Baptist University, Riverside, CA 92504, USA.ORCID 0000-0001-7067-4500
Antonella BertucciDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
David Caba MolinaDivision of Surgical Oncology, Department of Surgery, Riverside University Health System-University of California Riverside, Moreno Valley, CA 92555, USA.ORCID 0000-0002-4359-3315
Amy NguyenProteomics Core, Institute for Integrative Genome Biology, University of California, Riverside, CA 92521, USA.
Quanqing ZhangProteomics Core, Institute for Integrative Genome Biology, University of California, Riverside, CA 92521, USA.
Kristopher E BoyleSchool of Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA.
William H R LangridgeDivision of Biochemistry, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Marcelo VazquezDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Nathan R WallDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.ORCID 0000-0002-3235-4386

Funding

Loma Linda University N/A
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options and poor survival outcomes. This study evaluated the anticancer potential of seco-duocarmycin SA (seco-DSA), a potent DNA-alkylating agent, alone and in combination with proton radiation in human GBM cell lines. Human glioblastoma cell lines T98G and LN18 were treated with varying concentrations of seco-DSA, proton radiation doses (2, 4, or 8 Gy), or both. Proton irradiation was delivered with a 250-MeV beam. Clonogenic survival, cell proliferation, and cell cycle distribution were analyzed using colony formation and flow cytometry assays. Proteomic analysis of LN18 cells was performed by LC-MS/MS followed by bioinformatic pathway analysis. Statistical significance was determined using a two-tailed unpaired

Indexed as

Brain NeoplasmsGlioblastomaIndolesProton TherapyApoptosisCell Line, TumorCell ProliferationCell SurvivalDuocarmycinsHumansProteomicsProtonsDuocarmycinsIndolesProtonscellular mechanismsglioblastoma multiformepotencyproton radiationseco-DSAsynergy

Identifiers

PMID41683948
PMCPMC12898174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.